Literature DB >> 8338995

School performance and intellectual outcome in adolescents with phenylketonuria.

J Weglage1, B Fünders, B Wilken, D Schubert, K Ullrich.   

Abstract

In a retrospective study, 34 treated adolescents with phenylketonuria and their relatives were tested with scale 2 of the Culture Fair Intelligence Test (CFT20) and self-developed questionnaire concerning their development in school. The patients also filled in the Anxiety Questionnaire for Children. With an IQ of 93.6, the patients reached a normal mean intellectual performance but this was significantly below the mean IQ of the general population (100, p < 0.01), the IQ of their mothers (98.2, p < 0.05), their fathers (105.4, p < 0.05) and their siblings (110.3, p < 0.05). The patients' IQs correlated significantly with the IQs of their mothers, the socio-economic status of their families, the quality of dietary control since birth and the serum phenylalanine concentration at the moment of testing. With respect to age at which the patients started school, type of school attended and number of school years which had to be repeated, there were no significant differences between the patients and their siblings. The patients did not display a markedly higher degree of general anxiety, nervousness at examination time or a greater reluctance to attend school.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8338995     DOI: 10.1111/j.1651-2227.1993.tb12759.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  9 in total

1.  Wechsler subscale IQ and subtest profile in early treated phenylketonuria.

Authors:  P V Griffiths; C Demellweek; N Fay; P H Robinson; D C Davidson
Journal:  Arch Dis Child       Date:  2000-03       Impact factor: 3.791

2.  Deficits in selective and sustained attention processes in early treated children with phenylketonuria--result of impaired frontal lobe functions?

Authors:  J Weglage; M Pietsch; B Funders; H G Koch; K Ullrich
Journal:  Eur J Pediatr       Date:  1996-03       Impact factor: 3.183

3.  Intelligence patterns among children with high-functioning autism, phenylketonuria, and childhood head injury.

Authors:  M Dennis; L Lockyer; A L Lazenby; R E Donnelly; M Wilkinson; W Schoonheyt
Journal:  J Autism Dev Disord       Date:  1999-02

4.  Health-related quality of life in children and adolescents with phenylketonuria: unimpaired HRQoL in patients but feared school failure in parents.

Authors:  Eva Thimm; Lisa Elena Schmidt; Katrin Heldt; Ute Spiekerkoetter
Journal:  J Inherit Metab Dis       Date:  2013-01-08       Impact factor: 4.982

5.  Behaviour and school achievement in patients with early and continuously treated phenylketonuria.

Authors:  B A Stemerdink; A F Kalverboer; J J van der Meere; M W van der Molen; J Huisman; L W de Jong; F M Slijper; P H Verkerk; F J van Spronsen
Journal:  J Inherit Metab Dis       Date:  2000-09       Impact factor: 4.982

6.  Intelligence and professional career in young adults treated early for phenylketonuria.

Authors:  H Schmidt; P Burgard; J Pietz; A Rupp
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

7.  Estimating the probability of IQ impairment from blood phenylalanine for phenylketonuria patients: a hierarchical meta-analysis.

Authors:  Christopher J Fonnesbeck; Melissa L McPheeters; Shanthi Krishnaswami; Mary Louise Lindegren; Tyler Reimschisel
Journal:  J Inherit Metab Dis       Date:  2012-11-30       Impact factor: 4.982

8.  Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU).

Authors:  Eva Simon; Martin Schwarz; Judith Roos; Nico Dragano; Max Geraedts; Johannes Siegrist; Gudrun Kamp; Udo Wendel
Journal:  Health Qual Life Outcomes       Date:  2008-03-26       Impact factor: 3.186

9.  Executive function in adolescents with PKU and their siblings: Associations with biochemistry.

Authors:  R Sharman; K Sullivan; R Young; J McGill
Journal:  Mol Genet Metab Rep       Date:  2015-08-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.